Effect of tolcapone on plasma levodopa concentrations after coadministration with levodopa/carbidopa to healthy volunteers

Clinical Neuropharmacology

Volumn 20, Issue 6, 1997, Pages 531-541

  Sedek G ^a,b   Jorga, K ^a,b   Schmitt, M ^a,b   Burns, R S ^c   Leese, P ^d  

^a HOFFMANN LA ROCHE INC   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c IQVIA   (United States)

^d VANDERBILT UNIVERSITY   (United States)

Author keywords

Catechol O Methyltransferase; Levodopa carbidopa; Pharmacokinetics; Tolcapone

Indexed keywords

BENSERAZIDE; CARBIDOPA PLUS LEVODOPA; LEVODOPA; TOLCAPONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 0030859712     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199712000-00005     Document Type: Article

References (21)

1. Männistö PT, Kaakkola S. Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease. Pharmacol Toxicol 1990;66:317-23.
2. Marsden CD. Parkinson's disease. Lancet 1990;335:948-52.
3. Tolosa ES, Valldeoriola F, Marti MJ. New and emerging strategies for improving levodopa treatment. Neurology 1994:(suppl 6)44:S35-45.
4. Nutt JG, Woodward WR. Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients. Neurology 1986;36:739-44.
5. Guldberg HC, Marsden CA. Catechol-O-methyltransferase: pharmacological aspects and physiological role. Pharmacol Rev 1975;27:135-94.
6. Männistö PT, Kaakkola S, Nissinen E, Linden I-B, Pohto P. Properties of novel effective and highly selective inhibitors of catechol-O-methyltransferase. Life Sci 1988;43:1465-71.
7. Bieck PR, Nilsson E, Antonin KH. Effect of the new selective COMT inhibitor CGP 28 014A on the formation of 3-O-methyldopa (3-OMD) in plasma of healthy subjects. J Neural Transm Suppl 1990;32:387-91.
8. Pentikäinen PJ, Vuorela A, Järvinen M, Wikberg T, Gordin A. Human pharmacokinetics of OR-462, a new catechol-O-methyltransferase inhibitor [Abstract]. Eur J Clin Pharmacol 1989; (suppl)36:A110.
9. Keränen T, Gordin A, Harjola VP, et al. The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 1993;16:145-56.
10. Dingemanse J, Jorga KM, Schmitt M, et al. Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin Pharmacol Ther 1995;57:508-17.
11. Zürcher G, Colzi A, Da Prada M. Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues. J Neural Transm Suppl 1990;32:375-80.
12. Da Prada M, Zürcher G, Kettler R, Colzi A. New therapeutic strategies in Parkinson's disease: inhibition of MAO-B by Ro 19-6327 and of COMT by Ro 40-7592. Adv Behav Biol 1991;39:723-32.
13. Timm U, Erdin R. Determination of the catechol-O-methyltransferase inhibitor Ro 40-7592 in human plasma by high-performance liquid chromatography with coulometric detection. J Chromatogr 1992;308:93-100.
14. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982.
15. Dingemanse J, Jorga K, Zürcher G, et al. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol 1995;40:253-62.
16. Zürcher G, Keller HH, Kettler R, et al. Ro 40-7592: a novel, very potent, and orally active inhibitor of catechol-O-methyltransferase. A pharmacological study in rats. Adv Neurol 1990;53:497-503.
17. Nissinen E, Tuominen R, Perhoniemi V, Kaakkola S. Catechol-O-methyltransferase activity in human and rat small intestine. Life Sci 1988;42:2609-14.
18. Karhunen T, Tilgmann C, Ulmanen I, Julkunen I, Panula P. Distribution of catechol-O-methyltransferase enzyme in rat tissues. J Histochem Cytochem 1994;42:1079-90.
19. Robertson DR, Renwick AG, Wood ND, et al. The influence of levodopa on gastric emptying in man. Br J Clin Pharmacol 1990;29:47-53.
20. Goodall M, Alton H. Dopamine (3-hydroxytyramine) metabolism in parkinsonism. J Clin Invest 1969;48:2300-8.
21. Kaakkola S, Gordin A, Järvinen M, et al. Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of I-dopa in healthy volunteers. Clin Neuropharmacol 1990;13:436-47.